Market News AIOpen the app

Wells Fargo says PTC Therapeutics is a good buy and raised its price target to $112.

OpinionRead the original at in.tradingview.com
Good for PTCT

Wells Fargo kept its favorable rating and raised its target from $109 to $112, a modest positive signal. The rating stayed the same, so the added confidence is limited.

PTCT · PTC Therapeutics, Inc.

AI read · Good for PTCT

The AI's read

The change suggests the analyst sees slightly more room for PTC shares to rise, but the rating did not change. The story gives no new company results, so this is a modest positive opinion, not proof that its business has improved.

Get alerts for PTCT

Follow PTC Therapeutics, Inc. (PTCT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PTCT
Free on the App Store and Google Play, or on the web.